---
template: overrides/main.html
---

# Marketing History

* 2012년 FoundationOne laboratory developed test (F1 LDT)를 이용한 상용 샘플 분석
* 2017년 Nov. F1CDx Premarket Approval (PMA) approved ``P170019``
* 2018년 미국에서 commercially available
* PMA supplements affecting 기록
	* [x] P170019/S005 : adding genomic loss of heterozygosity (LOH)
	* [x] P170019/S004 : LYNPARZA (olaparib) in ovarian cancer patients with BRCA 1/2 alterations
	* [x] P170019/S008 : TAGRISSO (osimertinib) in NSCLC patients with EGFR exon 19 deletion and EGFR exon 21 L858R alteration
	* [x] P170019/S009 : MSI 결과에 대한 고지 내용 변경
	* [x] P170019/S006 : PIQRAY (alpelisib) in breast cancer patients with PIK3CA alterations
	* [x] P170019/S010 : second site in Morrisville, NC
	* [x] P170019/S013 : PEMZYRE (pemigatinib) in cholangiocarcinoma patients with FGFR2 fusion
	* [x] P170019/S011 : TABRECTA (capmatinib) in NSCLC patients with MET single nucleotide variants and indels that lead to MET exon 14 skipping
	* [x] P170019/S015 : LYNPARZA (olaparib) in mCRPC patients with mutations in HRR genes
	* [x] P170019/S016 : KEYTRUDA (pembrolizumab) in patients with solid tumors TMB at the cut-off of 10 mut/Mb
	* [x] P170019/S017 : VITRAKVI (larotrectinib) in patients with solid tumors neurotrophic tyrosine receptor kinases genes NTRK1, NTRK2, or NTRK3 fusions
